These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26549010)

  • 1. Daclatasvir for the treatment of chronic hepatitis C.
    Degasperi E; Aghemo A; Colombo M
    Expert Opin Pharmacother; 2015; 16(17):2679-88. PubMed ID: 26549010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
    Herbst DA; Reddy KR
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
    Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
    Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.
    McCormack PL
    Drugs; 2015 Apr; 75(5):515-24. PubMed ID: 25721433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV NS5A replication complex inhibitors.
    Gao M; O'Boyle DR; Roberts S
    Curr Opin Pharmacol; 2016 Oct; 30():151-157. PubMed ID: 27643675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Rizza SA
    Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclatasvir: potential role in hepatitis C.
    Lee C
    Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
    Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
    Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
    Clausznitzer D; Harnisch J; Kaderali L
    Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatitis C virus genotype 3-infection.
    Pol S; Vallet-Pichard A; Corouge M
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
    Lee SH; Moon JS; Pak BY; Kim GW; Lee W; Cho H; Kim S; Kim SJ; Oh JW
    Sci Rep; 2018 Aug; 8(1):12469. PubMed ID: 30127498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS5A inhibitors in the treatment of hepatitis C.
    Pawlotsky JM
    J Hepatol; 2013 Aug; 59(2):375-82. PubMed ID: 23567084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
    Pelosi LA; Voss S; Liu M; Gao M; Lemm JA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
    Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
    J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.